Our Pipeline
Target class
Indication
Molecule
Program
Discovery
Preclinical
Phase i/ii
Phase iii
Cytokines
Solid Tumors
IL-12
IL-15
Undisclosed
Undisclosed
ANK-101
ANK-102
ANK-103
ANK-104
Antibodies
Solid Tumors
CD40
Undisclosed
Undisclosed
ANK-201
ANK-202
ANK-203
Bi-Agonists
Solid tumors
CD40-IL-2
Undisclosed
Undisclosed
ANK-301
ANK-302
ANK-303
Lead Product Candidate: Tolododekin alfa (ANK-101)
IL-12 is a highly potent proinflammatory cytokine, but its therapeutic use has been limited by toxicity. There have been no approved IL-12 therapies.
Tolododekin alfa (ANK-101) is an investigational, first-in-class interleukin-12 (IL-12)-anchored immunotherapy.
In preclinical studies, anchored immunotherapy demonstrated:
- Therapeutic activity across various murine tumor models with prolonged retention in tumors for several weeks and no evidence of toxicity
- A favorable safety profile with a 29% objective response rate and 47% durable disease control rate in canines with advanced melanoma
Our Phase 1 data highlight our differentiated approach with clear competitive advantages in tolerability, and anti-tumor activity in a range of cancers.